Detect Early. Intervene Sooner. Achieve Better Outcomes.
ImpediMed (impedimed.com) earns a Brand Analyzer score of 72 out of 100, placing it in the Brand-Ready tier among Healthcare brands, Technology brands. Among 2305 Healthcare brands analyzed, ImpediMed ranks in the 73rd percentile (category average 68, leader 95). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 90/100, Digital Presence 76/100, Visual Identity 96/100, Messaging Clarity 95/100, Trust Foundation 69/100, AI Discoverability 91/100, Brand Authority 27/100.
ImpediMed is an Australian healthcare technology company founded in 1999 and headquartered in Brisbane, Australia. The company develops bioimpedance spectroscopy (BIS) devices designed for the early detection, assessment, and intervention in chronic diseases. Its flagship product, the SOZO® Digital Health Platform, is FDA-cleared and non-invasively measures fluid status and tissue composition. ImpediMed serves clinicians and healthcare providers treating conditions such as lymphedema, cancer survivorship, and weight-related health issues.
| Brand Name | ImpediMed |
|---|---|
| Domain | impedimed.com |
| Industry | Healthcare, Technology |
| Founded | 1999 |
| Headquarters | Brisbane, Australia |
| Main Competitors | InBody, Tanita, Bodystat, RJL Systems, Seca |
Moz Domain Authority 40/100 vs category average 29 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #4,196,478 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "ImpediMed’s bioimpedance spectroscopy (BIS) devices accurately and noninvasively aid for early detection, assessment, and intervention in chronic diseases." (Meta description: 18 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on LinkedIn, YouTube, Instagram; no detected presence on Facebook, X (Twitter), GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
ImpediMed scores 48/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
ImpediMed has a limited AI-visibility profile at 48/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is trust (71/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #4,196,478 (Tranco) and a Moz Domain Authority of 40/100. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
ImpediMed offers the SOZO® Digital Health Platform, which is its primary product. It is described as an FDA-cleared Bioimpedance Spectroscopy (BIS) technology that non-invasively measures fluid status and tissue composition in healthy and unhealthy patient populations. More broadly, ImpediMed develops bioimpedance spectroscopy (BIS) devices intended for the early detection, assessment, and intervention in chronic diseases. The SOZO platform functions as a digital health solution targeting clinical environments.
Sources: ImpediMed official site
ImpediMed's main competitors include InBody, Tanita, Bodystat, RJL Systems, Seca. These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: ImpediMed official site
ImpediMed is an Australian healthcare technology company founded in 1999 and based in Brisbane, Australia. It specializes in bioimpedance spectroscopy (BIS) technology, developing medical devices that non-invasively aid in the early detection, assessment, and intervention of chronic diseases. The company's SOZO® Digital Health Platform is FDA-cleared and is described as the only BIS technology cleared by the FDA that measures fluid status and tissue composition in both healthy and unhealthy patient populations.
Sources: ImpediMed official site
Popular alternatives to ImpediMed include InBody, Tanita, Bodystat, RJL Systems, Seca. Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: ImpediMed official site
ImpediMed develops and provides bioimpedance spectroscopy (BIS) devices and digital health platforms that non-invasively measure fluid status and tissue composition in patients. These tools are designed to support clinicians in the early detection, assessment, and intervention of chronic diseases such as lymphedema and weight-related health conditions. The company's technology enables personalized care and monitoring for cancer survivors and individuals managing chronic conditions, targeting healthcare providers as its primary users.
Sources: ImpediMed official site
ImpediMed has limited AI-search visibility, scoring 48/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 71, recommendation 69). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: ImpediMed official site
ImpediMed was founded in 1999. ImpediMed operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
ImpediMed and InBody are competitors in Healthcare. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: ImpediMed official site
ImpediMed is known for its SOZO® Digital Health Platform, which is the only FDA-cleared Bioimpedance Spectroscopy (BIS) technology designed to non-invasively measure fluid status and tissue composition. The company is recognized as a leader in non-invasive bioimpedance spectroscopy technology for early detection and personalized care in chronic disease management, particularly in areas such as lymphedema assessment and cancer survivorship care.
Sources: ImpediMed official site
ImpediMed's products are used by clinicians and healthcare providers. Specifically, the target audience includes medical professionals treating cancer survivors, wellness patients, and individuals managing chronic conditions such as lymphedema and weight-related health issues. The SOZO® Digital Health Platform is designed for clinical settings where providers need non-invasive tools to measure fluid status and tissue composition for patient monitoring and disease management.
Sources: ImpediMed official site
ImpediMed scores 69/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: ImpediMed official site
ImpediMed's SOZO® Digital Health Platform holds FDA clearance, which indicates that the technology has met regulatory standards for safety and effectiveness in the United States market. The company positions its BIS devices as accurate and non-invasive tools for clinical use. FDA clearance is a meaningful indicator of credibility in the medical device industry. However, no additional third-party assessments, clinical trial outcomes, or independent reviews are provided in the available facts to further assess trustworthiness.
Sources: ImpediMed official site
ImpediMed can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: ImpediMed official site
Based on available facts, ImpediMed's SOZO® Digital Health Platform is notable for being the only FDA-cleared Bioimpedance Spectroscopy technology for non-invasive measurement of fluid status and tissue composition. Its unique regulatory status and applicability to chronic disease management - including lymphedema and cancer survivorship - distinguish it among clinical tools. The platform's ability to serve both healthy and unhealthy patient populations makes it broadly applicable to clinicians and healthcare providers managing a range of conditions.
Sources: ImpediMed official site
Ranked closest to ImpediMed: ImagineSoftware (72/100), Humana (72/100), Inspiren (72/100), IO Health (72/100).
A step up - brands to learn from: Zipline (81/100), Zimmer Biomet (81/100).
Category leader: Dassault Systèmes (95/100).